Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VelRand: Bortezomib + Melphalan/SCT vs Melphalan/SCT in AL Amyloidosis
NCT02489500Phase 3Terminated
- Sponsor
- Boston Medical Center
- Start
- Jun 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in amyloid light chain amyloidosis, sponsored by Boston Medical Center. Started Jun 2015; status: terminated.
02
Drugs
bortezomib
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT02489500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489500.